4992 related articles for article (PubMed ID: 12117397)
41. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
[TBL] [Abstract][Full Text] [Related]
42. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
Prentice RL; Chlebowski RT; Stefanick ML; Manson JE; Pettinger M; Hendrix SL; Hubbell FA; Kooperberg C; Kuller LH; Lane DS; McTiernan A; Jo O'Sullivan M; Rossouw JE; Anderson GL
Am J Epidemiol; 2008 May; 167(10):1207-16. PubMed ID: 18372396
[TBL] [Abstract][Full Text] [Related]
43. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
44. Postmenopausal hormone therapy: cardiovascular risks.
Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
[TBL] [Abstract][Full Text] [Related]
45. Health risks outweigh benefits for combined estrogen plus progestin. Clinical trial stopped early in major study.
American Medical Association
Ginecol Obstet Mex; 2002 Aug; 70():411-2. PubMed ID: 12449905
[No Abstract] [Full Text] [Related]
46. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.
Herrington DM; Werbel BL; Riley WA; Pusser BE; Morgan TM
J Am Coll Cardiol; 1999 Jun; 33(7):2030-7. PubMed ID: 10362210
[TBL] [Abstract][Full Text] [Related]
47. Women's health. The vanishing promises of hormone replacement.
Enserink M
Science; 2002 Jul; 297(5580):325-6. PubMed ID: 12130763
[No Abstract] [Full Text] [Related]
48. Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial.
Chlebowski RT; Barrington W; Aragaki AK; Manson JE; Sarto G; OʼSullivan MJ; Wu D; Cauley JA; Qi L; Wallace RL; Prentice RL
Menopause; 2017 Feb; 24(2):133-141. PubMed ID: 27749739
[TBL] [Abstract][Full Text] [Related]
49. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
Lemay A
J Obstet Gynaecol Can; 2002 Sep; 24(9):711-5. PubMed ID: 12360366
[TBL] [Abstract][Full Text] [Related]
50. Effect of estrogen therapy on gallbladder disease.
Cirillo DJ; Wallace RB; Rodabough RJ; Greenland P; LaCroix AZ; Limacher MC; Larson JC
JAMA; 2005 Jan; 293(3):330-9. PubMed ID: 15657326
[TBL] [Abstract][Full Text] [Related]
51. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
52. Breast cancer after use of estrogen plus progestin in postmenopausal women.
Chlebowski RT; Kuller LH; Prentice RL; Stefanick ML; Manson JE; Gass M; Aragaki AK; Ockene JK; Lane DS; Sarto GE; Rajkovic A; Schenken R; Hendrix SL; Ravdin PM; Rohan TE; Yasmeen S; Anderson G;
N Engl J Med; 2009 Feb; 360(6):573-87. PubMed ID: 19196674
[TBL] [Abstract][Full Text] [Related]
53. Recent epidemiological evidence relevant to the clinical management of the menopause.
Shapiro S
Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
[TBL] [Abstract][Full Text] [Related]
54. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
[TBL] [Abstract][Full Text] [Related]
55. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
Rossouw JE; Prentice RL; Manson JE; Wu L; Barad D; Barnabei VM; Ko M; LaCroix AZ; Margolis KL; Stefanick ML
JAMA; 2007 Apr; 297(13):1465-77. PubMed ID: 17405972
[TBL] [Abstract][Full Text] [Related]
56. What pharmacists need to know about the women's health initiative estrogen plus progestin trial.
Saseen JJ; Hansen LB
Am J Health Syst Pharm; 2003 Feb; 60(3):281-4. PubMed ID: 12613239
[No Abstract] [Full Text] [Related]
57. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS).
Simon JA; Lin F; Vittinghoff E; Bittner V;
Ann Epidemiol; 2006 Feb; 16(2):138-45. PubMed ID: 16039873
[TBL] [Abstract][Full Text] [Related]
58. Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial.
Manson JE; Aragaki AK; Bassuk SS; Chlebowski RT; Anderson GL; Rossouw JE; Howard BV; Thomson CA; Stefanick ML; Kaunitz AM; Crandall CJ; Eaton CB; Henderson VW; Liu S; Luo J; Rohan T; Shadyab AH; Wells G; Wactawski-Wende J; Prentice RL;
Ann Intern Med; 2019 Sep; 171(6):406-414. PubMed ID: 31499528
[TBL] [Abstract][Full Text] [Related]
59. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.
Wild RA; Wu C; Curb JD; Martin LW; Phillips L; Stefanick M; Trevisan M; Manson JE
Menopause; 2013 Mar; 20(3):254-60. PubMed ID: 23435021
[TBL] [Abstract][Full Text] [Related]
60. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics.
Grady D; Applegate W; Bush T; Furberg C; Riggs B; Hulley SB
Control Clin Trials; 1998 Aug; 19(4):314-35. PubMed ID: 9683309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
